Policy Analysis Inc (PAI)
Industry / private company
Location:
Brookline, MA,
United States (USA) (US)
ISNI: 0000000105579179
ROR: https://ror.org/02jxrxr40
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024)
Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al.
Journal article
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial (2022)
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al.
Journal article
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021)
Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al.
Journal article
Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020)
Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al.
Conference contribution